The economic and public health impact of intellectual property licensing of medicines for low-income and middle-income countries: a modelling study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The economic and public health impact of intellectual property licensing of medicines for low-income and middle-income countries: a modelling study

Published:2022-02 Issue:2 Volume:7 Page:e169-e176
ISSN:2468-2667
Container-title:The Lancet Public Health
language:en
Short-container-title:The Lancet Public Health

Author:

Morin Sébastien,Moak Hannah Barron,Bubb-Humfryes Oliver,von Drehle Christian,Lazarus Jeffrey V,Burrone Esteban

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health

Reference15 articles.

1. Essential medicines for universal health coverage;Wirtz;Lancet,2017

2. Does the political will exist to bring quality-assured and affordable drugs to low- and middle-income countries?;Beck;Glob Health Action,2019

3. Projected savings through public health voluntary licences of HIV drugs negotiated by the Medicines Patent Pool (MPP);Juneja;PLoS One,2017

4. Effect of voluntary licences for hepatitis C medicines on access to treatment: a difference-in-differences analysis;Simmons;Lancet Glob Health,2019

5. A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries;Waning;J Int AIDS Soc,2010

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intellectual property licensing of therapeutics during the COVID-19 crisis: lessons learnt for pandemic preparedness and response;Globalization and Health;2024-07-02

2. Pandemic preparedness and response: a new mechanism for expanding access to essential countermeasures;Health Economics, Policy and Law;2024-05-31

3. Feasibility, safety, efficacy and potential scaling-up of sofosbuvir-based HCV treatment in Central and West Africa: (TAC ANRS 12311 trial);Scientific Reports;2024-05-03

4. Feasability and effectiveness of scaling up hepatitis-C treatment in West and Central Africa: the TAC ANRS 12311 clinical trial;2023-11-28

5. Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis;The Lancet;2023-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3